Jacobio Pharmaceuticals Group Co. Ltd. has received a milestone payment of $20 million from Abbvie Inc. for dosing the first two patients in the U.S. for a global phase I/IIa study of SHP2 inhibitor JAB-3312 in combination with PD-1 antibody pembrolizumab and MEK inhibitor binimetinib, taking another step forward in the global SHP2 race.
PERTH, Australia – Immutep Ltd. announced a AU$60 million (US$45.1 million) capital raise via two tranches to progress two clinical programs of its lead immunotherapy, eftilagimod alpha, to registration studies.
Lenz Therapeutics Inc. emerged from stealth mode with $47 million in series A financing to fund its mission to bring a drug therapy to bear on farsightedness, a problem that affects much of humanity, at one point or another.
Biopharmas raising money in public or private financings, including: Biophytis, Celsion, Elevation, GH Research, Inhibikase, Kempharm, Monte Rosa, Protagonist, Rapt.
CAR T specialist Carsgen Therapeutics Holdings Ltd.’s shares started trading on the Hong Kong Stock Exchange on June 18, helping the company raise HK$3.1 billion (US$400 million) from an IPO that will allow it to advance its phase II-stage BCMA CAR T therapy candidate, CT-053, in multiple markets.
Biopharmas raising money in public or private financings, including: Alzamend, Ambrx, Anacardio, Atai, Century, Cyteir, Hutchmed, Karolinska, Neuvocor, PDS.
Kahr Medical Ltd.’s $46.5 million financing provides runway to advance its multifunctional immunotherapeutic pipeline. The proceeds will be used to for clinical development of its lead asset, DSP-107, a first-in-class CD47x41BB targeting fusion protein to treat solid tumors and blood cancers through multiple phase I/II studies.
Apollo Therapeutics LLC has completed a $145 million financing to develop its business model, based on building a portfolio of drugs through relationships with U.K. academic institutions.
RSS
